Abstract
Our aim was to study the prognostic value ofgrowth hormone (GH)-stimulated insulin-like growthfactor-I (IGF-I) and IGF-binding protein-3 (IGFBP-3)generation in patients with compensated [group 1 (N = 8) with a Child-Pugh (CP) score of 5-8] anddecompensated postnecrotic liver cirrhosis [group 2 (N= 7) with a CP score of 9-12]. Serum levels of IGF-I,GH-binding protein (GHBP), and IGFBP-3 were measuredbefore and 24 hr after a single subcutaneous injectionof recombinant human GH (rhGH, 0.14 units/kg). Patients(mean age 56 years) were followed prospectively forthree years. Six patients (40%) died during the follow-up period, of whom half had a CP score<9. Mean serum IGF-I levels 24 hr after rhGHinjection (group 1 vs group 2, 17.4 ± 6.8 vs 7.4± 0.7 nmol/liter) predicted survival with 93%accuracy. Levels <10 nmol/liter portended a poorprognosis, with 15% survival at one year, whereas levels>10 nmol/liter had a 100% survival rate at one andtwo years, respectively. Baseline IGF-I (9.98 ± 2.0 vs 6.38 ± 0.8 nmol/liter), GHBP (9.2± 3 vs 5.7 ± 0.8%/50 μl), and IGFBP-3serum levels at baseline (1.7 ± 0.3 vs 0.86± 0.2 mg/liter) and at 24 hr (2.04 ± 0.38vs 0.99 ± 0.3 mg/liter) did not add to the predictive value ofstimulated IGF-I levels at 24 hr and were less accuratein predicting the outcome in comparison to CP score(80%). We conclude that stimulated IGF-1 < 10nmol/liter may be a true predictor of a negative prognosisin patients with liver cirrhosis.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
REFERENCES
Christensen E, Schlichting P, Fauerholdt L, Gluud C, Andersen PK, Juhl E, Poulsen H, Tygstrup N: Prognostic value of Child-Turcotte criteria in medically treated cirrhosis. Hepatology 4:430 - 435, 1984
Dickson ER, Grambsch PM, Fleming TR, Fisher LD, Langworthy A: Prognosis in primary biliary cirrhosis: Model for decision making. Hepatology 10:1- 7, 1989
Merkel C, Gatta A, Zoli M, Bolognesi M, Angeli P, Iervese T, Marchesini G, Ruol A: Prognostic value of galactose elimination capacity, aminopyrine breath test, and ICG clearance in patients with cirrhosis. Comparison with the Pugh score. Dig Dis Sci 36:1197- 1203, 1991
Merkel C, Marchesini G, Fabbri A, Bianco S, Bianchi G, Enzo E, Sacerdoti D, Zoli M, Gatta A: The course of galactose elimination capacity in patients with alcoholic cirrhosis: Possible use as a surrogate marker for death. Hepatology 24:820 - 823, 1996
Baker AL, Kotake AN, Schoeller DA: Clinical utility of breath tests for the assessme nt of hepatic function. Semin Live r Dis 3:318 - 329, 1983
Wahllander A, Mohr S, Paumgartner G: Asse ssment of hepatic function. Comparison of caffeine clearance in serum and saliva during the day and at night. J Hepatol 10:129 - 137, 1990
Meyer-Wyss B, Renner E, Luo H, Scholer A: Assessme nt of lidocaine metabolite formation in comparison with other quantitative liver function tests. J Hepatol 19:133- 139, 1993
Virgolini I, Muller C, Hobart J, Scheithauer W, Ange lberger P, Bergmann H, O'Grady J, Sinzinger H: Liver function in acute viral hepatitis as determined by a hepatocyte-specific ligand: 99mTc-galactosyl-neoglycoalbumin. Hepatology 15:593- 598, 1992
Ghent CN, Wall WJ: The lidocaine monoe thyl glycine xylidide test of liver function. Live r Transplant Surg 2:242- 245, 1996
Jalan R, Hayes PC: Quantitative tests of liver function. Aliment Pharmacol Ther 9:263- 270, 1995
Le Roith D: Insulin-like growth factors. N Engl J Med 336:633- 640, 1997
Daughaday WH, Rotwein P: Insulin-like growth factors I and II. Peptide, messenge r ribonucleic acid and gene structures, serum, and tissue concentrations. Endocrinol Rev 10:68 - 91, 1989
Shmueli E, Stewart M, Alberti G, Record C: Growth hormone, insulin-like growth factor-I, and insulin resistance in cirrhosis. Hepatology 1994;19:322- 328.
Scharf J-G, Schmitz F, Frystyk J, Skjaerbaek C, Heidrun M, Blum WF, Ramadori G, Hartmann H: Insulin-like growth factor-I se rum concentrations and patterns of insulin-like growth factor binding proteins in patients with chronic liver disease. J Hepatol 25:689 - 699, 1996
Assy N, Hochberg Z, Amit T, Shenn-Orr Z, Enat R, Baruch Y: Growth hormone stimulated insulin-like growth factor (IGF) I and IGF-binding protein-3 in liver cirrhosis. J Hepatol 27:796 - 802, 1997.
Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R: Transe ction of the oesophagus for bleeding oesophage al varices. Br J Surg 60:646 - 649, 1973
Amit T, Barkey RJ, Youdim MBH, Hochberg Z: A new and convenient assay of growth hormone-binding protein activity in human serum. J Clin Endocrinol Metab 71:474 - 480, 1990
Sugimura T, Tsuji Y, Sakamoto M, Kotoh K, Fukutomi T, Sakai H, Sakamoto S, Akazawa K, Nose Y, Nawata H: Longterm prognosis and prognostic factors of liver cirrhosis in the 1980s. J Gastroenterol Hepatol 9:154 - 161, 1994
Urbain D, Muls V, Thys O, Ham HR: Aminopyrine bre ath test improves long-term prognostic evaluation in patients with alcoholic cirrhosis in Child classe s A and B. J Hepatol 22:179 - 183, 1995
Moller S, Becker U, Juul A, Skakkebaek NE, Christensen E, EMALD Group: Prognostic value of insulinlike growth factor I and its binding protein in patients with alcohol-induced liver disease. Hepatology 23:1073- 1078, 1996
Baruch Y, Amit T, Hertz P, Enat R, Youdim MBH, Hochberg Z: De cre ased serum growth hormone-binding protein in patients with liver cirrhosis. J Clin Endocrinol Metab 73:777- 780, 1991
Rights and permissions
About this article
Cite this article
Assy, N., Hochberg, Z., Enat, R. et al. Prognostic Value of Generation of Growth Hormone-Stimulated Insulin-Like Growth Factor-I (IGF-I) and Its Binding Protein-3 in Patients with Compensated and Decompensated Liver Cirrhosis. Dig Dis Sci 43, 1317–1321 (1998). https://doi.org/10.1023/A:1018828412631
Issue Date:
DOI: https://doi.org/10.1023/A:1018828412631